In the News
Here are some of the latest noteworthy articles and studies related to Adial’s work.
Adial Pharma Moves Alcohol Use Disorder Drug Toward Phase III With Refined Biomarker Strategy
Continue Reading
Adial Pharmaceuticals Achieves Key Milestone With Analytical Validation Of Genetic Test For AD04 Phase 3 Trials
Continue Reading
Dr. Brigitte Robertson, MD CMO, Adial Pharmaceuticals - Combating Alcohol Use Disorder
Watch Interview
AD04 for Alcohol Use Disorder: Favorable Feedback From FDA Following End of Phase 2 Meeting
Continue Reading
August in Review: Updates on the Psychiatric Treatment Pipeline
Continue Reading
Adial Pharma Prepares for Phase III Trial of Genetically Targeted Alcohol Use Disorder Drug
Continue Reading
End of Phase 2 Meeting With the FDA: Adial Prepares to Advance AD04 for Alcohol Use Disorder
Continue Reading
Combating Misconceptions About Alcohol Use Disorder: In Conversation With Brigitte Robertson, MD
Continue Reading
FDA Has Granted Request for End of Phase 2 Meeting to Discuss Alcohol Use Disorder Treatment, AD04
Continue Reading
FDA Backs Adial Pharmaceuticals' Strategy for AD04 Addiction Therapy
Continue Reading
Positive FDA Feedback for Proposed In Vitro Bridging Strategy for Alcohol Use Disorder Treatment, AD04
Continue Reading
Adial Is Filling The Gap In Alcohol Use Disorder Treatment With Repurposed Drug
Continue Reading
Patent Issued for Methods of Identifying Patients With Substance Use-Associated Genetic Markers, Treatment With AD04
Continue Reading
AD04 Advancing to Phase III Amid Promising Results in Alcohol Use Disorder
Continue Reading
AD04 Study Highlights Consistent Bioavailability and Safety for Alcohol Use Disorder Treatment
Continue Reading
Positive Results From Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Continue Reading
Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down
Continue Reading
The Escalator: Emergent BioSolutions, CureVac, Kyowa Kirin and more
Continue Reading
Running a country or a business—leaders must ‘honor the room,’ says Wharton professor
Continue Reading
To read the full story, subscribe or sign in. Appointments and advancements for Nov. 5, 2024
Continue Reading
Adial Pharma Developing Regulatory Strategy for CDx Genetic Test for Alcohol Use Disorder Drug
Continue Reading
Dosing Starts in Pharmacokinetics Study of AD04 for Alcohol Use Disorder
Continue Reading
EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
Continue Reading
BioBreakthroughs #34 - Cary Claiborne, CEO of Adial Pharmaceuticals
Watch Interview
Chutes & Ladders—Hardy replaces BioMarin’s commercial chief in first big move as CEO
Continue Reading
Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering
Continue Reading
An Evolving ‘Opinion’ Landscape: New Paths—and Synergies—for Pharma KOLs & DOLs
Continue Reading
Conversations Life Science Leaders Aren't Having S3:E3 Leading through growth and uncertainty with wisdom – with Cary Claiborne
Listen Here
Genetically Targeted Therapeutic Looks Promising for Alcohol Use Disorder
Continue Reading
Adial at a clinical fork in the road after flunking phase 3 trial for its alcohol addiction med
Continue Reading
July 20 Quick Takes: Multiomics-driven cancer newco Auron raises $48M series A
Continue Reading
Beyond Increments: Black Perspectives on Representation in the Life Sciences
Continue Reading
Interview with Adial Pharmaceuticals CEO Bill Stilley
Listen Here
Developing Serotonin-3 Receptor Blocker to Treat Alcohol Use Disorder with Bill Stilley Adial Pharmaceuticals
Listen Here
An oral pill for alcohol abuse vies to enter a quickly evolving market
Continue Reading
Adial is Leveraging Genomics to Treat “Pervasive” Alcohol Use Disorder
Continue Reading
Sharing of these articles does not constitute Adial’s endorsement of facts or opinions stated therein.
